Posted
CEO Emma Walmsley is in the midst of splitting the 68 bln pound drugmaker. Spinning off the consumer division from the core pharmaceutical unit may unlock value and deliver cash for takeovers. Aimee Donnellan argues the drastic surgery still leaves a lot of heavy lifting.
02:28
02:19
01:46
02:58
01:07
02:03
01:54
03:31
03:11
01:49
01:41
01:58
00:55
02:11
01:31
01:50
01:14
01:14
01:02
01:43
01:12
01:12
02:43
01:18
01:48
01:01
02:49
01:08
01:24
00:52
01:10
01:19
01:02
01:05
01:18
01:08
01:18
02:04
01:29
01:28
03:01
01:34
01:47
02:37
02:20
01:35
02:18
00:46
02:02
01:06
01:43
02:16
01:31
03:17
01:31
02:13
01:28
01:07
01:01
01:01
01:26
01:31
01:27
00:47
01:58
01:24
01:00
01:32
02:03
01:41
01:54
01:21
00:43
01:46